Atlas Trials

X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

Clinical trial NCT03215693 · UNKNOWN

Trial details

NCT number
NCT03215693
Sponsor
Betta Pharmaceuticals Co., Ltd.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Non-Small Cell Lung Cancer
Start date
2017-09-28
Primary completion
2020-03-09
Enrollment
152

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.